💡 在您使用本产品前请认真阅读说明书,这对您顺利完成实验很有帮助。
|
🏷️ 产品编码
RB9T37015165
|
🧬 中文名称
抗人DLL4和VEGF双特异性参考抗体
|
|
📝 英文名称
Anti-Human DLL4 & VEGF Bispecific Reference Antibody
| |
|
📦 形态
Liquid
|
🧪 纯度
>95% purity as determined by SDS-PAGE.
|
|
🔹 内毒素水平
Please contact the lab for this information.
| |
|
🔬 应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
| |
|
🧫 表达系统
Mammalian Cells
|
🔢 登录号
Q9NR61 & P15692
|
|
🔹 宿主种属
Humanized
|
🔹 克隆性
Monoclonal
|
|
🔹 抗体亚型
IgG1-kappa
|
🔹 纯化方式
Protein A/G purified from cell culture supernatant.
|
|
🔹 浓度
1mg/ml
|
🔹 种属反应性
Human
|
|
🔹 靶标
Delta-like protein 4, Drosophila Delta homolog 4, Delta4, DLL4, Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
|
🔹 背景信息
Dilpacimab (formerly ABT-165), a novel dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways. Here, we present safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data from a phase I study (trial registration ID: NCT01946074) of dilpacimab in patients with advanced solid tumors. Eligible patients (≥18 years) received dilpacimab intravenously on days 1 and 15 in 28-day cycles at escalating dose levels (range, 1.25–7.5 mg/kg) until progressive disease or unacceptable toxicity.
|
|
🏷️ 别名
Bispecific, ABT-165, PR-1283233, 1791420-09-1
| |
🧴 储存缓冲液
0.01M PBS, pH 7.4.
❄️ 稳定性和储存
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
⚠️ For research use only. Not suitable for clinical or therapeutic use.